SWL Medizin GmbH

SWL Medizin GmbH specializes in extracorporeal shock wave therapy (ESWT) devices. These include systems like the Mercury (used for multiple therapeutic applications) and Migress, as well as the SWL-Pioneer, which is likely designed for specific clinical uses. The devices are primarily used in urology (e.g., lithotripsy for kidney stones), orthopedics (tissue regeneration), and dermatology (pain management). Shock waves are generated externally to treat conditions without invasive surgery.

SWL Medizin GmbH is based in Germany, which places its devices under the jurisdiction of the European Union’s regulatory framework. Since the company’s products are listed in eudamed, the EU’s medical device registry, they comply with EU MDR (Medical Device Regulation) requirements. This registry ensures traceability and transparency for authorities, though individual device authorizations depend on their classification and compliance with EU directives.

SWL Medizin GmbH’s devices fall into two EU risk classes: Class III (for lithotripsy systems, which involve high-risk procedures like breaking kidney stones) and Class IIa (for therapeutic shock wave applications, such as pain relief or tissue regeneration). The classification determines regulatory scrutiny: Class III devices require rigorous clinical evidence and conformity assessments, while Class IIa devices undergo less stringent but still thorough evaluation. This classification ensures patient safety by aligning device risk with oversight rigor.

Yes, SWL Medizin GmbH’s devices are registered in eudamed, the EU’s official medical device database. This listing means the company’s products are traceable, and their details (e.g., UDI, manufacturer info) are publicly accessible for regulatory authorities, healthcare providers, and patients. While registration doesn’t imply authorization, it demonstrates compliance with EU requirements for transparency and accountability in the medical device supply chain.